| Title |
Lipoprotein(a)—clinical aspects and future challenges
|
|---|---|
| Published in |
Clinical Research in Cardiology Supplements, March 2015
|
| DOI | 10.1007/s11789-015-0075-z |
| Pubmed ID | |
| Authors |
Bilgen Kurt, Muhidien Soufi, Alexander Sattler, Juergen R. Schaefer |
| Abstract |
Lipoprotein(a) (Lp(a)) was first described by K. Berg and is known for more than 50 years. It is an interesting particle and combines the atherogenic properties of low-density lipoprotein (LDL)-cholesterol as well as the thrombogenic properties of plasminogen inactivation. However, due to technical problems and publication of negative trials the potential role of Lp(a) in atherosclerosis was severely underestimated. In recent years our understanding of the function and importance of Lp(a) improved. Interventional trials with niacin failed to demonstrate any benefit of lowering Lp(a); however, several studies confirmed the residual cardiovascular disease (CVD) risk of elevated Lp(a). LDL/Lp(a) apheresis is able to lower Lp(a) and some new drugs under development should help us to lower Lp(a) in the near future. It will be important to follow this with hard endpoint trials. Until then most clinicians recommend the use of an aggressive LDL-lowering approach in patients with high Lp(a). Since most of these patients with high Lp(a) might have manifested atherosclerosis anyway, we would also consider the use of acetylsalicylic acid. |
Mendeley readers
The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 17 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 2 | 12% |
| Unknown | 15 | 88% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 1 | 6% |
| Unknown | 16 | 94% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 March 2024.
All research outputs
#3,330,434
of 23,106,934 outputs
Outputs from Clinical Research in Cardiology Supplements
#4
of 17 outputs
Outputs of similar age
#43,486
of 257,524 outputs
Outputs of similar age from Clinical Research in Cardiology Supplements
#1
of 5 outputs
Altmetric has tracked 23,106,934 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 17 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.8. This one scored the same or higher as 13 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 257,524 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them